Systematic discovery of complex insertions and deletions in human cancers

Nature Medicine

Volumn 22, Issue 1, 2016, Pages 97-104

  Ye, Kai ^a   Wang, Jiayin ^a   Jayasinghe, Reyka ^b   Lameijer, Eric Wubbo ^c   McMichael, Joshua F ^a   Ning, Jie ^a   McLellan, Michael D ^a   Xie, Mingchao ^a,b   Cao, Song ^a   Yellapantula, Venkata ^a,b   Huang, Kuan Lin ^a,b   Scott, Adam ^a,b   Foltz, Steven ^a,b   Niu, Beifang ^a   Johnson, Kimberly J ^d   Moed, Matthijs ^c   Slagboom, P Eline ^c   Chen, Feng ^b,e   Wendl, Michael C ^a,b   Ding, Li ^a,b,e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^e Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARID1A GENE; ARTICLE; ATRX GENE; BREAST CANCER; CONTROLLED STUDY; EGFR GENE; EXOME; FRAMESHIFT MUTATION; GATA3 GENE; GENE STRUCTURE; HUMAN; INDEL MUTATION; KIDNEY CANCER; KIT GENE; KMT2D GENE; MET GENE; MUTATIONAL ANALYSIS; NEOPLASM; ONCOGENE; PIK3R1 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PTEN GENE; STRUCTURE ANALYSIS; TISSUE SPECIFICITY; TP53 GENE; TUMOR GENE; VHL GENE; WORKFLOW; DATA MINING; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; PROCEDURES; TUMOR CELL LINE;

ARID1A PROTEIN, HUMAN; ATRX PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA HELICASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GATA3 PROTEIN, HUMAN; MET PROTEIN, HUMAN; MLL2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3R1 PROTEIN, HUMAN; PROTEIN P53; PTEN PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TUMOR PROTEIN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

CELL LINE, TUMOR; DATA MINING; DNA HELICASES; DNA-BINDING PROTEINS; GATA3 TRANSCRIPTION FACTOR; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDEL MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84954401021     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4002     Document Type: Article

References (35)

1. Levy, S. et al. The diploid genome sequence of an individual human. PLoS Biol. 5, e254 (2007).
2. Sudmant, P.H. et al. An integrated map of structural variation in 2,504 human genomes. Nature 526, 75-81 (2015).
3. Kloosterman, W.P. et al. Characteristics of de novo structural changes in the human genome. Genome Res. 25, 792-801 (2015).
4. Roerink, S.F., van Schendel, R., Tijsterman, M. Polymerase-mediated end joining of replication-associated DNA breaks in C. elegans. Genome Res. 24, 954-962 (2014).
5. Koole, W. et al. A polymerase-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites. Nat. Commun. 5, 3216 (2014).
6. Yu, A.M., McVey, M. Synthesis-dependent microhomology-mediated end joining accounts for multiple types of repair junctions. Nucleic Acids Res. 38, 5706-5717 (2010).
7. Han, S.W. et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23, 2493-2501 (2005).
8. Lara-Guerra, H. et al. Phase 2 study of preoperative gefitinib in clinical stage 1 non-small-cell lung cancer. J. Clin. Oncol. 27, 6229-6236 (2009).
9. Ruppert, A.M. et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur. Respir. J. 33, 436-440 (2009).
10. Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391-2405 (2013).
11. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
12. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 490, 61-70 (2012).
13. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
14. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
15. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
16. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
17. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear-cell renal-cell carcinoma. Nature 499, 43-49 (2013).
18. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
19. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
20. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
21. Pleasance, E.D. et al. A comprehensive catalog of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
22. Robinson, J.T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
23. Dees, N.D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
24. Frampton, G.M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023-1031 (2013).
25. Kanchi, K.L. et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat. Commun. 5, 3156 (2014).
26. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
27. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumor types. Nature 505, 495-501 (2014).
28. Pritchard, C.C. et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 16, 56-67 (2014).
29. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302-308 (2014).
30. Rehm, H.L. et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15, 733-747 (2013).
31. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
32. Sordella, R., Bell, D.W., Haber, D.A., Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
33. Ye, K., Kosters, W.A., Ijzerman, A.P. An efficient, versatile and scalable pattern-growth approach to mine frequent patterns in unaligned protein sequences. Bioinformatics 23, 687-693 (2007).
34. Ye, K., Schulz, M.H., Long, Q., Apweiler, R., Ning, Z. Pindel: a pattern-growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009).
35. Zhang, Y. et al. PASSion: a pattern-growth algorithm-based pipeline for splice junction detection in paired-end RNA-seq data. Bioinformatics 28, 479-486 (2012).